Introduction
============

The decline in fertility in humans has been a medical concern for \~25 years ([@b1-mmr-17-03-3481]). The development of *in vitro* fertilization (IVF) has emerged as the most successful treatment for fertility problems. However, despite the use of adjuvant therapies, the cumulative percentage of live births remains at only \~40% worldwide ([@b2-mmr-17-03-3481]). The major factor limiting the success of IVF procedures is embryo implantation ([@b3-mmr-17-03-3481]). Accumulating data has shown that low pregnancy rates, despite high fertility rates, are primarily due to implantation failure ([@b4-mmr-17-03-3481],[@b5-mmr-17-03-3481]). Each failure of *in vitro* fertilization has significant effects on the quality of life and mental wellbeing of patients, in addition to being a financial burden. Therefore, further investigations into the causes and mechanisms of implantation failure are warranted.

Embryo implantation, which requires a viable blastocyst and uterine receptivity, involves a series of steps, including the interaction and invasion of the blastocyst to the endometrium. The cross-talk between the embryo and the endometrium is essential for successful implantation ([@b2-mmr-17-03-3481]). As implantation is the result of interactions between the blastocyst and endometrium, it is considered that this process is initiated as soon as a chemical interaction is established between the embryo and endometrium. The interaction between the blastocyst and endometrium begins immediately following entry of the embryo into the endometrial cavity and prior to active penetration of the endometrium by the developing blastocyst ([@b6-mmr-17-03-3481]). In this respect, it has been reported that embryo-specific signaling is present prior to the embryo entering the endometrial cavity and making intimate contact with the endometrium ([@b7-mmr-17-03-3481]--[@b10-mmr-17-03-3481]).

Preimplantation factor (PIF) is a unique peptide, which is secreted only by viable embryos. PIF is detected first in the early stages, and is present throughout the duration of pregnancy in several species of mammal, where it is expressed in the placenta ([@b11-mmr-17-03-3481],[@b12-mmr-17-03-3481]). It has been noted that synthetic PIF (sPIF), which replicates native PIF function, affects key processes in early pregnancy implantation, including modulating peripheral immune cells, contributing to the maternal adaptation to pregnancy, and creating a favorable immune environment shortly following fertilization ([@b13-mmr-17-03-3481]). Of note, sPIF can exert a positive autocrine effect on trophoblast invasion, and the invasion of trophoblast cells is enhanced by exposure to sPIF ([@b14-mmr-17-03-3481]). Therefore, PIF is considered to promote or rescue placental invasion and represents a significant advance in reproductive technology.

In the present study, isobaric tags for relative and absolute quantification (iTRAQ) technology, combined with liquid chromatography-electrospray ionization-tandem mass spectrometry (LCESI-MS/MS) analysis, were used to identify key proteins that react with PIF, and western blot analysis was used for confirmation of findings. Using these measurements, the present study aimed to develop a profile of PIF-reactive proteins, and provide valuable understanding and insight into the molecular mechanism underlying the effect of PIF on the promotion of trophoblast invasion.

Materials and methods
=====================

### Reagents and antibodies

Eight-plex iTRAQ reagent kits were acquired from Applied Biosystems; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Monoclonal antibodies against human PIF (18-802-392017) were obtained from GenWay (San Diego, CA, USA) and polyclonal antibodies against GAPDH (ab9485), MYH10 (ab684), tubulin, β5 class I (TUBB5; ab15568) and heat shock protein family D1 (HSPD1; ab46798) were purchased from Abcam (Cambridge, UK). MYH10-specific Stealth Select RNAi™ small interfering (si)RNA (NM_005964.3), Stealth RNAi™ Negative Control siRNA (cat. no. 12935-400) and Lipofectamine 2000 transfection reagent were obtained from Thermo Fisher Scientific, Inc. CytoSelect™ 24-Well Cell Migration and Invasion Assay kits (8 µm, colorimetric format) were purchased from Cell Biolabs (San Diego, CA, USA).

### Cell lines and tissues

The HTR-8/SVneo cell line was derived from an explant culture of human first-trimester placenta and was used in the present study ([@b15-mmr-17-03-3481]). HTR-8/SVneo cells, HEK293 cells (Sigma; Merck Millipore, Darmstadt, Germany) HEC-1-B cells (Shanghai Institute of Cell Biology, Shanghai, China) were cultured at 37°C, under 5.0% CO~2~, in RPMI-1640 medium (Nanjing KeyGen Biotech. Co. Ltd., Nanjing, China) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 100 IU/ml of penicillin. A total of 20 male and 20 female Sprague-Dawley rats (7 weeks old, 200--250 g), obtained from the Animals Experiment Center of Chongqing Medical University, were housed under controlled conditions (25±2°C, 60±10% relative humidity and 12-h light/dark cycle) with free access to tap water and food throughout the experimental period. Following 1 week of acclimation on an American Institute of Nutrition-93G diet, the male rats were randomly allocated into two groups of 10 animals per group: Healthy control group, and experimental group, in which rats receiving sterilization by surgical ligation. The breeders were paired every evening between 3:00 and 5:00 p.m., and were separated every morning between 9:00 and 10:00 a.m., followed by vaginal plug checks. After 4 days, all rats were euthanized with sodium pentobarbital (1 mg/kg bodyweight i.p.), endometrial tissues were extracted and fixed for 24 h in 4% paraformaldehyde in 1X PBS at 4°C. All tissues were frozen with liquid nitrogen and preserved at −196°C. All rats received humane care in accordance with the guidelines of the Animal Usage Committee of the Chongqing Medical University (Chongqing, China), which approved the study prior to commencement.

### Peptide synthesis

The partial characterization and PIF assay information were as described previously ([@b16-mmr-17-03-3481]). Synthetic PIF, the purity of which was documented using high-performance liquid chromatography and mass spectrometry as 95%, was produced by Biosynthesis, Inc. (Lewisville, TX, USA). Synthetic PIF (sPIF; MVRIKPGSANKPSDD), intralipid and scrambled PIF (PIFscr; GRVDPSNKSMPKDIA) and biotin-labeled ligands of \>95% purity were also generated.

### Invasion assays

Invasion assays were performed using a Cell Invasion Assay kit (Cell Biolabs, Inc., Beijing, China), according to the manufacturer\'s protocol. The HTR-8/SVneo (50,000) cells were resuspended in medium with PIF or PIFscr (100 ng/ml). As determined using trypan blue exclusion under a light micros\'cope (CK40; Olympus Corporation, Tokyo, Japan), \~1×10^5^ viable HTR-8/SVneo cells were seeded into the upper chamber of a 24-well plate with polycarbonate membrane inserts. The numbers of cells to invade through the ECM Matrix gel were determined using CyQuant GR fluorescent dye (560 nm).

### Co-immunoprecipitation (CoIP) and iTRAQ labeling

The HEK293 cells were trypsinized and lysed in 500 µl lysis buffer (Western blot and immunoprecipitation; Beyotime Institute of Biotechnology, Inc., Haimen, China) on ice for 20 min. The cell lysates were centrifuged for 15 min at 17,949 × g and 4°C to remove debris. Subsequently, 1 mg of lysates (1 µg/µl) was mixed with biotin-labeled synthetic PIF or PIFscr overnight at 4°C, and then precleared with 50 µl ulfo-NHS-SS-avidin protein A-Sepharose beads (Pierce; Thermo Fisher Scientific, Inc.) for 2 h at 4 °C. The beads were pelleted and washed three times with lysis buffer. The bound proteins were eluted in SDS sample buffer and quantified by 2D Quantification kit assay (GE Healthcare Life Sciences, Little Chalfont, UK) according to the manufacturer\'s protocol. Then 20 µg protein per well was subjected to 10% SDS-PAGE and analyzed by immunoblotting. The eluted protein (100 µg) was precipitated from each pooled group, dissolved in dissolution buffer, denatured with 2% SDS, cysteine blocked, digested with 2 µg of sequencing grade modified trypsin, and labeled using iTRAQ reagents (PIF, 117 tag; PIFScr, 118 tag) provided with the iTRAQ kit (AB Sciex Analytical Instrument Trading Co., Shanghai, China; [Fig. 1](#f1-mmr-17-03-3481){ref-type="fig"}). For the parallel experiment, the same sample set was labeled with iTRAQ reagents 119 and 121, respectively ([Fig. 1](#f1-mmr-17-03-3481){ref-type="fig"}). The peptides from each sample set were mixed prior to subsequent analysis.

### Peptide fractionation

The labeled peptides were fractionated by immobilized-pH-gradient isoelectric focusing (IPG-IEF), as previously described ([@b17-mmr-17-03-3481],[@b18-mmr-17-03-3481]). Briefly, the samples were dissolved in a Pharmalyte (GE Healthcare Life Sciences, Chalfont, UK) and urea solution, rehydrated on a pH 3--10 IPG strip, and subjected to IEF at 68 kV/h using an IPG phor system (GE Healthcare Life Sciences). The peptides were extracted from the gel using an acetonitrile (ACN) and formic acid solution ([@b19-mmr-17-03-3481]). The fractions were lyophilized, and purified with SPE Discovery DSC-18 columns (Supelco, Inc., Bellefonte, PA, USA). The purified peptides were re-lyophilized and stored at −20°C until use.

### Mass spectrometry

The purified peptide fractions were reconstituted in solvent A, comprising water/ACN (98:2 v/v) with 0.1% formic acid, and separated using a C18-PepMap column (Thermo Fisher Scientific, Inc.) with a solvent gradient of 2--100% Buffer B (0.1% formic acid and 98% acetonitrile) in Buffer A at a flow rate of 0.3 µl/min. The peptides were electrosprayed using a nanoelectrospray ionization source at an ion spray voltage of 2,300 eV, and were analyzed using the NanoLC-ESI-Triple TOF 5600 system (AB Sciex Analytical Instrument Trading Co.). The mass spectrometer was set in the positive ion mode at a mass range of 300--1,800 m/z. The two most intensely charged peptides \>20 counts were selected for tandem MS/MS at a dynamic exclusion of 30 sec ([@b19-mmr-17-03-3481]). Data were processed using ProteinPilot v2.0 (AB Sciex Analytical Instrument Trading Co.) and compared with the UniProt database (<http://www.uniprot.org/>). Cysteine modified by methane thiosulfate was specified as a fixed modification. Protein identification was based on a threshold protein score of \>1.3. For quantitation, at least two unique peptides with 95% confidence and a P-value of \<0.05 were required.

### Bioinformatics analysis

The Gene Ontology was analyzed using the PANTHER classification system (<http://www.pantherdb.org/>) to determine biological processes, protein classes and molecular functions.

### Western blot analysis

To validate the results of the proteomic analysis, the same sets of protein samples were subjected to immunoblot analyses. Each non-depleted sample was diluted 10-fold with 10 mM PBS. Two equal volumes of diluted samples (20 µg) were separated by 10% SDS-PAGE, following which one volume was stained with Coomassie blue for protein loading determination and the other volume was transferred onto PVDF membranes for immunoblotting. The membranes were blocked in 5% skim milk in Tris-buffered saline with Tween-20 at room temperature for 1 h, and incubated with primary antibodies against GAPDH (1:2,500), PIF (1:200), MYH10 (1:2,000), TUBB5 (1:1,000) and HSPD1 (1:10,000) at 4°C overnight. The membranes were then incubated with HRP-conjugated goat anti-mouse immunoglobulin (Ig) G (sc-2005; 1:5,000) or goat anti-rabbit IgG (sc-2004; 1:5,000; both from Santa Cruz Biotechnology, Santa Cruz, CA, USA) at room temperature for 1 h. Finally, the membranes were visualized using the ChemiDoc MP imaging system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The expression levels of PIF, MYH10 and HSPD1 in the endometrial tissues of rats were detected using the same immunoblotting procedure. The quantification of target proteins was determined using densitometry and normalized against GAPDH (Multi Sciences Biotech Co., Ltd., Hangzhou, China).

### MYH10 siRNA transfection, Transwell and wound healing assays

When the cultures of HEC-1-B cells grown in 10 cm dishes with or without medium spiked with PIF or PIFscr (100 ng/ml) reached 95% confluence, they were transfected with 100 nm of MYH10-specific siRNA or a negative control siRNA (cat. no. 12935-400) using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. Cell viability was determined using a trypan blue exclusion assay, and only cells with \>95% viability were used for subsequent assays. The Transwell assays were performed as described previously ([@b20-mmr-17-03-3481]). For the wound healing assays, the cells were cultured in 6-well plates until they reached 100% confluence. A 200-µl pipette tip was used to scratch the cell monolayer, followed by washing with growth medium to remove debris. The resultant gap was monitored for up to 24 h under light microscopy (Eclipse 80i; Nikon Corporation, Tokyo, Japan).

### Statistical analysis

Statistical analyses were performed using SPSS software v13.0 (SPSS Inc., Chicago, IL, USA). Quantitative variables are presented as the mean ± standard deviation. Comparisons between groups were analyzed using Student\'s t-test or a Mann-Whitney U test. Qualitative variables are presented as counts and percentages, which were analyzed using the χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### PIF promotes HTR-8/Svneo cell invasion

To confirm the bioactivity of synthetic PIF in tumor cell motility, HTR-8/Svneo cells were resuspended in medium with PIF or PIFscr (100 ng/ml). A Matrigel invasion assay revealed that PIF increased the invasiveness of HTR-8/Svneo cells by 40--52%, compared with the controls (P\<0.05; [Fig. 2](#f2-mmr-17-03-3481){ref-type="fig"}).

### MS identification and iTRAQ quantification of aberrantly expressed proteins

To investigate the key proteins reacting with PIF, quantitative proteomics analysis using iTRAQ tags was performed. At least two peptides were used for quantification and protein identification. For Protein Pilot-based database searching and identification, the threshold \[unused protscore (conf)\] was set to achieve 95% confidence at 5% false discovery rate. The protein identification threshold, a ProtScore value \>1.3, was used to attain a confidence of 95%. When the proteins were classified as significantly regulated or not, an additional \>1.3 (1×1.3) or \<0.77 (1/1.3)-fold cutoff was applied to all iTRAQ ratios to minimize false positives when determining whether proteins were overexpressed or underexpressed. This cutoff value was used as overall technical variation of data from the duplicate experiments was estimated \<30% (data not shown), and, in other investigations using the iTRAQ approach, this value has been widely used.

A total of 70 unique proteins were successfully identified by using at least two peptides (data not shown). A total of 21 proteins were differentially expressed in the PIF binding proteins of HEK 293 ([Table I](#tI-mmr-17-03-3481){ref-type="table"}), of which 12 were upregulated and nine were downregulated in the PIF binding proteins, compared with the PIFscr proteins.

Gene Ontology analysis using PANTHER suggested that the majority of the differentially expressed proteins were enzymes or signaling molecules, followed by cell development regulators and cellular structure-related proteins ([Fig. 3A and B](#f3-mmr-17-03-3481){ref-type="fig"}).

### Verification of aberrant expression of MYH10, TUBB5 and HSPD1

To determine the reliability of the iTRAQ analysis data, western blot and CoIP analyses were performed to confirm whether PIF interacts with MYH10, TUBB5 and HSPD1. As expected, MYH10, TUBB5 and HSPD1 were captured when using PIF as the bait protein ([Fig. 4A-E](#f4-mmr-17-03-3481){ref-type="fig"}).

### Expression of MYH10, TUBB5 and HSPD1 in tissues

Western blot analysis was used to assess the expression of MYH10, TUBB5 and HSPD1 in the endometrial tissues of the experimental rats. The results indicated that MYH10, TUBB5 and HSPD1 were upregulated in the endometrial tissues of the pregnant rats ([Fig. 5](#f5-mmr-17-03-3481){ref-type="fig"}).

### MYH10 knockdown attenuates HEC-1-B cell migration and invasion

To examine the role of MYH10 in tumor cell motility, protein expression was inhibited in HEC-1-B cell lines using RNA interference. The effective silencing with MYH10-specific siRNA was confirmed in the HEC-1-B cells using western blot analysis ([Fig. 6A](#f6-mmr-17-03-3481){ref-type="fig"}). Transfection of the HEC-1-B cells with MYH10-specific siRNA resulted in a 57--70% decrease in the ability to close scratch wounds, compared with the cells in the control siRNA group (P\<0.05; [Fig. 6B](#f6-mmr-17-03-3481){ref-type="fig"}). The Matrigel invasion assay also revealed that MYH10-specific siRNAs decreased the invasiveness of HEC-1-B cells by 47--52%, and the migration capacity of the HEC-1-B cells by 45--51%, compared with the controls (P\<0.05 [Fig. 6C and D](#f6-mmr-17-03-3481){ref-type="fig"}).

Discussion
==========

Placental development is dependent on adequate invasion of the first-trimester trophoblast into the maternal decidua to sufficiently remodel maternal spiral arteries ([@b21-mmr-17-03-3481]). By contrast, incomplete invasion has been implicated in a variety of adverse pregnancy outcomes, including fetal loss, fetal growth restriction and preeclampsia ([@b22-mmr-17-03-3481]). The implantation of embryos into the maternal endometrium and placental formation with trophoblast invasion require a complex interplay of embryo-derived cellular signaling for establishing maternal immune receptivity, and for preparing the embryo itself to be suitable for invasion ([@b14-mmr-17-03-3481],[@b23-mmr-17-03-3481]). As an embryo-specific peptide, PIF is produced as early as the two-cell stage ([@b11-mmr-17-03-3481]), and is understood to facilitate trophoblast invasion, eventually affecting placental development in the peri-implantation period ([@b14-mmr-17-03-3481]).

In the present study, a protein profile was used to elucidate the molecular mechanism by which PIF promotes trophoblast invasion. Utilizing the iTRAQ proteomics approach, proteins interacting with PIF were identified. The use of immunoprecipitation confirmed that MYH10, TUBB5 and HSPD1 potentially interacted with PIF. Functional investigations indicated that MYH10 tended to act on the migration and invasion of HTR-8 trophoblast cells. The results of the present study revealed that the iTRAQ method for large-scale protein quantification was credible and amenable to high throughput investigations, and that the novel proteins uncovered may describe the PIF-relative interaction network in promoting trophoblast invasion, thus advancing the knowledge of its functional mechanism.

Certain aspects of the implantation process resemble tumor invasion, whereas the implantation process consists of a precisely controlled series of events. The initiation of implantation requires that the trophoblast attaches, via its apical plasma membrane, to the apical plasma membrane of the uterine epithelium. As apical plasma membranes of epithelia are usually non-adhesive, cells can express the mesenchymal/fibroblastoid phenotype to allow the cells to move individually, or express the epithelioid phenotype to migrate as sheets. The trophoblast of blastocysts alters its motility apparatus to accommodate the invasion process. Collective cell migration requires the dynamic reorganization of cell-cell junction complexes and associated cytoskeletal structures to allow cells to alter their positions without losing cell-cell contacts. The invasion of trophoblast cells occurs through the stroma in a regulated manner by the remodeling of the extracellular matrix. A specialized submembrane filamentous network supports stable cell-cell binding between these cells ([@b24-mmr-17-03-3481]). Myosin II is an actin-binding protein, which is central in the control of cell adhesion, cell migration and tissue architecture. Acting as an actin cytoskeleton, MYH10 regulates cell polarity, adhesion and migration. MYH10 can also affect cancer progression via the initial acquisition of malignant properties by normal cells, invasion of adjacent tissues and metastasis to distant sites ([@b25-mmr-17-03-3481],[@b26-mmr-17-03-3481]). These processes involve the dynamic remodeling of the actin cytoskeleton and the interaction of the cell with its environment. MYH10 facilitates protrusion formation via the generation of retrograde flow of actin in the lamellum, which is connected to the lamellipodium ([@b27-mmr-17-03-3481],[@b28-mmr-17-03-3481]). Inhibition of the activity of MYH10 with blebbistatin, or the genetic deletion of MYH10, markedly decreases the rate of actin retrograde flow in the lamellum ([@b27-mmr-17-03-3481],[@b28-mmr-17-03-3481]) and inhibits the coalescence of actin into proto-bundles at the lamellipodium-lamellum interface ([@b29-mmr-17-03-3481],[@b30-mmr-17-03-3481]), which increases protrusiveness. According to the role of MYH10 in regulating metastasis, actin cytoskeleton-mediated cell migration and invasion can support the PIF-induced promotion of trophoblast invasion.

The present study identified several potential molecules to assist in explaining the mechanism of PIF-mediated trophoblast invasion. Taken together, the interaction between PIF and MYH10 significantly enhanced the invasion and migration capabilities of HTR-8 trophoblast cells. These findings, coupled with the known embryonic effects of sPIF, suggest that this peptide requires investigation to promote or rescue placental invasion, and are a significant advance in reproductive technology.
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![Flow chart of the isobaric tags for relative and absolute quantification proteomic approach. PIF, preimplantation factor; PIFScr, intralipid and scrambled PIF; IEF, isoelectric focusing; LC/MS/MS, liquid chromatography-tandem mass spectrometry.](MMR-17-03-3481-g00){#f1-mmr-17-03-3481}

![Effect of synthetic PIF on HTR-8/SVneo cell invasion. \*P\<0.05 vs. PIFscr group. Bars indicate standard deviation. PIF, preimplantation factor; PIFScr, intralipid and scrambled PIF.](MMR-17-03-3481-g01){#f2-mmr-17-03-3481}

![PIF-associated proteins categorized by (A) molecular function and (B) cellular component. PIF, preimplantation factor; GO, Gene Ontology.](MMR-17-03-3481-g02){#f3-mmr-17-03-3481}

![Biochemical purification and identification of PIF-associated protein factors. PIF protein complexes from cytoplasmic extracts of HEK293 cells were mixed with biotin-labeled PIF (lanes 1, 4, 7, 10 and 13) or PIFscr (lanes 2, 5, 8, 11 and 14). In lanes 3, 6, 9, 12 and 15, no biotin-labeled PIF or PIFscr was added. Anti-biotin IPs were analyzed using western blot analysis with (A) anti-biotin (lanes 1--3), (B) anti-PIF (lanes 4--6), (C) anti-MYH10 (lanes 7--9), (D) anti-TUBB5 (lanes 10--12) and (E) anti-HSPD1 (lanes 13--15). PIF, preimplantation factor; PIFScr, intralipid and scrambled PIF; IP, immunoprecipitate; MYH10, and myosin heavy chain 10; TUBB5, tubulin, β5 class I; HSPD1, heat shock protein family D1; Neg., negative control.](MMR-17-03-3481-g03){#f4-mmr-17-03-3481}

![Representative western blots of the expression of PIF and MYH10 in decidual tissues from five cases of false pregnancy rats and true pregnancy rats. PIF and MYH10 were markedly upregulated in decidual tissues of the true pregnancy rats. PIF, preimplantation factor; MYH10, and myosin heavy chain 10; TUBB5, tubulin, β5 class I.](MMR-17-03-3481-g04){#f5-mmr-17-03-3481}

![Role of MYH10 in PIF-induced invasion and migration of HEC-1-B cells. (A) Western blot analysis. \*P\<0.05 vs. Neg. siRNA group. Bars indicate standard deviation. (B) Wound healing assay. (C) Matrigel invasion assay. \*P\<0.05 vs. PIFscr group. Bars indicate standard deviation. (D) Migration assay. \*P\<0.05 vs. PIFscr group. Bars indicate standard deviation. PIF, preimplantation factor; PIFScr, intralipid and scrambled PIF; MYH10, and myosin heavy chain 10; siRNA, small interfering RNA; Neg. negative control.](MMR-17-03-3481-g05){#f6-mmr-17-03-3481}

###### 

List of differentially expressed proteins, identified using iTRAQ analysis, between PIF and PIFscr binding of cytoplasmic extracts in HEK293 cells.

  n     Accession   Gene symbol   Protein name                                Peptides (95%)   Cytoplasmic extract of HEK293+biotin-labeled PIF: cytoplasmic extract of HEK293+biotin-labeled PIFscr 117:118^[a](#tfn1-mmr-17-03-3481){ref-type="table-fn"}^ (fold)   Cytoplasmic extract of HEK293+biotin-labeled PIF: cytoplasmic extract of HEK293+biotin-labeled PIFscr 119:121^[a](#tfn1-mmr-17-03-3481){ref-type="table-fn"}^ (fold)
  ----- ----------- ------------- ------------------------------------------- ---------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
    1   P05067      APP           Amyloid βA4 protein isoform d                   5            67.0963                                                                                                                                                                70.4693
    2   O94832      MYO1D         Myosin-Id                                     27               4.8306                                                                                                                                                                 4.4463
    3   P35580      MYH10         Isoform 1 of Myosin-10                      741                4.1281                                                                                                                                                                 4.1305
    4   Q12965      MCM3AP        80 kDa MCM3-associated protein                  3              3.3729                                                                                                                                                                 2.6546
    5   P68371      TUBB2C        Tubulin β-2C chain                            14               1.8707                                                                                                                                                                 2.4434
    6   O00159      MYO1C         Isoform 1 of myosin-Ic                          2              1.7865                                                                                                                                                                 2.0137
    7   P67936      TPM4          Isoform 1 of tropomyosin α-4 chain            52               1.3062                                                                                                                                                                 1.6904
    8   P07437      TUBB          Tubulin β chain                               13               2.1281                                                                                                                                                                 1.6444
    9   P68363      TUBA1B        Tubulin α-1B chain                            11               1.7219                                                                                                                                                                 1.6144
  10    Q9NYL9      TMOD3         Tropomodulin-3                                13               1.5560                                                                                                                                                                 1.5704
  11    P07195      LDHB          L-lactate dehydrogenase B chain                 2              1.4450                                                                                                                                                                 1.4588
  12    P06753      TPM3          Isoform 2 of tropomyosin α-3 chain            75               1.3428                                                                                                                                                                 1.3428
  13    P02533      KRT14         Keratin, type I cytoskeletal 14                 7              0.5546                                                                                                                                                                 0.7112
  14    P13645      KRT10         Keratin, type I cytoskeletal 10               35               0.1393                                                                                                                                                                 0.6918
  15    Q7Z406      MYH14         Isoform 1 of myosin-14                      297                0.5105                                                                                                                                                                 0.6252
  16    P08779      KRT16         Keratin, type I cytoskeletal 16                 7              0.4786                                                                                                                                                                 0.6026
  17    P04264      KRT1          Keratin, type II cytoskeletal 1               49               0.2051                                                                                                                                                                 0.5754
  18    P35908      KRT2          Keratin, type II cytoskeletal 2 epidermal     18               0.4699                                                                                                                                                                 0.5200
  19    P08238      HSP90AB1      Heat shock protein HSP 90-β                     2              0.2489                                                                                                                                                                 0.1459
  20    P02042      HBD           Hemoglobin subunit δ                            6              0.5754                                                                                                                                                                 0.0738
  21    P69905      HBA2; HBA1    Hemoglobin subunit α                            9              0.7586                                                                                                                                                                 0.0136

117:118 and 119:121 refer to the relative level of protein expression in PIF with respect to PIFscr. Statistical calculation for iTRAQ-based detection and relative quantification were calculated using the Paragon Algorithm of ProteinPilot software. iTRAQ, isobaric tags for relative and absolute quantification; PIF, preimplantation factor; PIFScr, intralipid and scrambled PIF.
